TFRC has been proposed as a tumor biomarker in a wide spectrum of malignancies, including B-cell lymphoma, pancreatic, esophageal, cervical as well as prostate cancers [31–36]. This evidence concerns the gene TFRC and B-cell non-Hodgkin lymphoma.